HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV

BACKGROUND & AIMS: Millions of people worldwide are infected chronically with HBV, which results in significant morbidity and mortality. Therapeutic vaccination is a strategy that aims to induce functional cure by restoring cellular immunity to HBV. Previously we have shown the candidate HBV imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Cargill, Tamsin, Cicconi, Paola, Brown, Anthony, Holland, Louise, Karanth, Benaka, Rutkowski, Kathryn, Ashwin, Emily, Mehta, Reena, Chinnakannan, Senthil, Sebastian, Sarah, Bussey, Louise, Sorensen, Henrik, Klenerman, Paul, Evans, Thomas, Barnes, Eleanor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543776/
https://www.ncbi.nlm.nih.gov/pubmed/37791379
http://dx.doi.org/10.1016/j.jhepr.2023.100885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543776/
https://www.ncbi.nlm.nih.gov/pubmed/37791379
http://dx.doi.org/10.1016/j.jhepr.2023.100885

Ejemplares similares